NasdaqGM:PTGXBiotechs
Why Protagonist Therapeutics (PTGX) Is Up 7.0% After First FDA Approval For ICOTYDE Psoriasis Drug
Protagonist Therapeutics recently held a special call to discuss the U.S. FDA approval of ICOTYDE (icotrokinra) for the treatment of moderate to severe plaque psoriasis, marking a major regulatory milestone for the company.
This approval highlights the company’s ability to successfully advance a novel therapeutic into the market for a serious, chronic skin condition with significant unmet patient needs.
We’ll now explore how the FDA approval of ICOTYDE for moderate to severe plaque psoriasis...